Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022. Key highlights in...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quar...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today I am discussing the six most aggressive growth stocks to buy in July. They reflect huge potential growth in their sales and/or their earnings. That means their valuations may be quite high, reflecting optimism about t...
Glaukos Corporation ( NYSE: GKOS ), a health equipment maker focused on eye diseases such as Glaucoma, is trading higher in the morning hours Tuesday after Stifel upgraded its shares to Buy from Hold citing sales gains in 2022. Following a survey of ophthalmologists, the a...
iRhythm Technologies ( NASDAQ: IRTC ), a maker of electrocardiogram (ECG) monitoring products, added ~11% in the pre-market Friday after the company issued its comments on the Medicare reimbursement rates proposed for 2023. The Centers for Medicare and Medicaid Services ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 42 nd ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler ...
Glaukos Corporation (GKOS) Q1 2022 Earnings Conference Call May 4, 2022, 4:30 PM ET Company Participants Tom Burns – Chairman & Chief Executive Officer Joe Gilliam – President & Chief Operating Officer Alex Thurman – Chief Financial Officer Chris Lewis – Vi...
Glaukos press release (NYSE:GKOS): Q1 Non-GAAP EPS of -$0.38 beats by $0.13. Revenue of $67.7M (-0.4% Y/Y) beats by $6.85M. For further details see: Glaukos Non-GAAP EPS of -$0.38 beats by $0.13, revenue of $67.7M beats by $6.85M
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2022. Key highlights in...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...